Leriglitazone, a PPARγ agonist, has been found to increase the protein level of frataxin and PGC-1α and its downstream target, glucose-regulated protein 75 (GRP75), in fibroblasts derived from patients with FRDA, contributing to restoration of mitochondrial function and biogenesis [137]. Here, FXN is linked to Friedreich ataxia.